Publications by authors named "Barry Bernstein"

Claim this Profile
H
HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals.
Gavin Cloherty, Daniel Cohen, Christoph Sarrazin, Heiner Wedemeyer, Stephane Chevaliez, Barry Bernstein

Antivir Ther· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
Amit Khatri, Rajeev M Menon, Thomas C Marbury, Eric J Lawitz, Thomas J Podsadecki, Barry M Bernstein

J Hepatol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy.
Christoph Sarrazin, Heiner Wedemeyer, Gavin Cloherty, Daniel E Cohen, Stephane Chevaliez, Barry Bernstein

J Virol Methods· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Pietro Andreone, Massimo G Colombo, Jeffrey V Enejosa, Iftihar Koksal, Peter Ferenci, Barry Bernstein

Gastroenterology· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
Fred Poordad, Christophe Hezode, Roger Trinh, Kris V Kowdley, Stefan Zeuzem, Barry Bernstein

N Engl J Med· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Stefan Zeuzem, Ira M Jacobson, Tolga Baykal, Rui T Marinho, Fred Poordad, Barry Bernstein

N Engl J Med· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Jordan J Feld, Kris V Kowdley, Eoin Coakley, Samuel Sigal, David R Nelson, Barry Bernstein

N Engl J Med· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
Kris V Kowdley, Eric Lawitz, Fred Poordad, Daniel E Cohen, David R Nelson, Barry Bernstein

N Engl J Med· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.
Eric Lawitz, Fred Poordad, Kris V Kowdley, Daniel E Cohen, Thomas Podsadecki, Barry Bernstein

J Hepatol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory study of oral combination antiviral therapy for hepatitis C.
Fred Poordad, Eric Lawitz, Kris V Kowdley, Daniel E Cohen, Thomas Podsadecki, Barry Bernstein

N Engl J Med· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of the lopinavir/ritonavir tablet 500/125 mg twice daily coadministered with efavirenz in healthy adult participants.
Juki Ng, Yi-Lin Chiu, Walid Awni, Barry Bernstein, Sonja J Causemaker

J Clin Pharmacol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.
Juan González-García, Daniel Cohen, Margaret Johnson, Louis Sloan, Linda Fredrick, Barry Bernstein

AIDS Res Hum Retroviruses· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks.
Roberto Zajdenverg, Thomas J Podsadecki, Sharlaa Badal-Faesen, Jaime Andrade-Villanueva, Joseph Gathe, Barry M Bernstein

J Acquir Immune Defic Syndr· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe.
Sibtain Rahim, Linda M Fredrick, Barbara A da Silva, Barry Bernstein, Martin S King

HIV Clin Trials· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.
Todd T Brown, Grace A McComsey, Martin S King, Roula B Qaqish, Barry M Bernstein

J Acquir Immune Defic Syndr· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks.
Joseph Gathe, Barbara A da Silva, Daniel E Cohen, Mona R Loutfy, Daniel Podzamczer, Barry Bernstein

J Acquir Immune Defic Syndr· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.
Rafael E Campo, Barbara A Da Silva, Laurent Cotte, Joseph C Gathe, Brian Gazzard, Barry M Bernstein

AIDS Res Hum Retroviruses· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.
D William Cameron, Barbara A da Silva, Jose R Arribas, Robert A Myers, Nicholaos C Bellos, Barry M Bernstein

J Infect Dis· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.
Sarah Palmer, Frank Maldarelli, Ann Wiegand, Barry Bernstein, George J Hanna

Proc Natl Acad Sci U S A· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.
Daniel Podzamczer, Martin S King, Cheri E Klein, Charles Flexner, Christine Katlama, Barry Bernstein

HIV Clin Trials· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
Sherie Masse, Xiaozhi Lu, Tatyana Dekhtyar, Liangjun Lu, Gennadiy Koev, Barry Bernstein

Antimicrob Agents Chemother· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
D William Cameron, Stephen Becker, Martin S King, Barbara da Silva, Cheri Klein, Barry Bernstein

J Antimicrob Chemother· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.
Martin S King, Barry M Bernstein, Sharon L Walmsley, Renslow Sherer, Judith Feinberg

J Infect Dis· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Dale J Kempf, Martin S King, Barry Bernstein, Paul Cernohous, Eric Bauer

J Infect Dis· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.
Joseph J Eron, Judith Feinberg, Harold A Kessler, Harold W Horowitz, Mallory D Witt, Barry Bernstein

J Infect Dis· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis